Retour sur lavenir.net
   NYXOAH 2.375 € (-3,06 %)     UMICORE 25.960 € (-0,84 %)     AB INBEV 71.740 € (-0,22 %)     COLRUYT 33.200 € (-0,78 %)     SOLVAY 26.200 € (+0,77 %)     KBC 114.350 € (+1,55 %)     KBC ANCORA 80.900 € (+2,15 %)     SOFINA 227.200 € (+1,52 %)     MELEXIS 81.800 € (+0,43 %)     SYENSQO 66.750 € (+0,38 %)     EVS BROADC.EQUIPM. 31.900 € (+2,41 %)     AGEAS 68.200 € (+0,15 %)     VGP 81.100 € (+1,00 %)     CAMPINE 239.000 € (+3,46 %)     BPOST 1.792 € (+1,36 %)     ONTEX GROUP 2.680 € (+0,75 %)     ONWARD MEDICAL 2.880 € (+1,77 %)     UCB 243.300 € (+0,54 %)     PROXIMUS 6.880 € (-0,29 %)     ARGENX SE 696.200 € (-0,68 %)     GIMV 49.700 € (+0,40 %)     AZELIS GROUP 10.230 € (-0,78 %)     RETAIL ESTATES 70.300 € (+0,43 %)     BARCO 9.185 € (+0,44 %)     D'IETEREN GROUP 171.600 € (+2,45 %)     GBL 81.650 € (+0,80 %)     LOTUS BAKERIES 10 860.000 € (+0,18 %)     CARE PROPERTY INV. 13.220 € (+0,30 %)     FAGRON 25.050 € (+0,20 %)     CENERGY 24.780 € (+3,16 %)     ELIA GROUP 139.400 € (+1,31 %)     AEDIFICA 72.000 € (+0,63 %)     SHURGARD 23.700 € (-0,84 %)     WDP 22.220 € (+0,91 %)     BELYSSE GROUP 0.560 € (+6,87 %)     ACKERMANS V.HAAREN 279.000 € (+1,82 %)     CMB.TECH 14.420 € (-1,10 %)     KINEPOLIS GROUP 29.500 € (+0,68 %)     MONTEA 68.000 € (+1,49 %)     RECTICEL 10.800 € (+0,75 %)     TINC 11.900 € (-3,09 %)     DECEUNINCK 2.070 € (+0,49 %)     TUBIZE-FIN 210.800 € (+1,44 %)     COFINIMMO 84.550 € (+0,59 %)     TITAN S.A. 48.320 € (+0,96 %)     WERELDHAVE BELGIUM 52.600 € (+0,77 %)     ATENOR 1.780 € (-0,84 %)     DEME GROUP 189.600 € (+1,39 %)     XIOR 27.450 € (+0,55 %)     VASTNED 29.600 € (+0,34 %)     BEKAERT 41.850 € (+0,97 %)     BANQUP GROUP 2.300 € (-6,12 %)     VIOHALCO 19.580 € (+2,73 %)     OXURION 0.004 € (0,00 %)     SIPEF 95.800 € (+0,63 %)     CIE BOIS SAUVAGE 313.000 € (0,00 %)     FLUXYS BELGIUM D 20.200 € (+1,76 %)     IBA 15.460 € (+0,52 %)     TESSENDERLO 21.350 € (-0,23 %)     ECONOCOM GROUP 1.550 € (0,00 %)  
   FDJ UNITED 23.150 € (+0,48 %)     BANIJAY GROUP 9.000 € (+2,51 %)     TONNER DRONES 0.039 € (+2,08 %)     NICOX 0.387 € (+0,13 %)     OPMOBILITY 15.650 € (+2,29 %)     CVC CAPITAL 13.310 € (+2,07 %)     UBISOFT ENTERTAIN 5.348 € (+1,21 %)     EXOSENS 64.900 € (+0,46 %)     SBM OFFSHORE 34.470 € (-1,01 %)     ARCELORMITTAL SA 57.740 € (+1,69 %)     SANOFI 76.650 € (-0,30 %)     L'OREAL 366.150 € (+1,24 %)     AIRWELL 1.250 € (+6,38 %)     BNP PARIBAS ACT.A 91.840 € (+2,12 %)     SES 8.795 € (-1,73 %)     MANITOU BF 21.000 € (+0,96 %)     ABL Diagnostics 3.420 € (-2,29 %)     DSM FIRMENICH AG 70.800 € (-0,98 %)     ATEME 13.450 € (+10,70 %)     DBT 0.042 € (-1,86 %)     BIOMERIEUX 73.900 € (+0,82 %)     HAFFNER ENERGY 0.222 € (+24,86 %)     KALRAY 12.440 € (+12,48 %)     NANOBIOTIX 36.700 € (+0,66 %)     AIR LIQUIDE 182.680 € (+1,28 %)     EDENRED 22.380 € (+0,63 %)     SAFRAN 298.500 € (+4,74 %)     VEOLIA ENVIRON. 35.180 € (+1,41 %)     PHILIPS KON 23.550 € (+0,77 %)     DASSAULT AVIATION 296.000 € (+1,58 %)     2CRSI 48.760 € (+4,41 %)     ARAMIS GROUP 3.040 € (+2,36 %)     MAGNUM 13.788 € (-0,73 %)     IPSOS 37.100 € (+0,92 %)     ENGIE 27.310 € (+0,52 %)     WORLDLINE 0.351 € (+9,82 %)     AIRBUS 173.660 € (+2,44 %)     CSG 18.440 € (-1,86 %)     AHOLD DEL 36.720 € (+0,19 %)     SOITEC 179.750 € (+1,35 %)     PROLOGUE 0.299 € (+4,91 %)     ASML HOLDING 1 422.000 € (+0,92 %)     THX PHARMA 3.620 € (+4,62 %)     HAL TRUST 175.800 € (+0,34 %)     BILENDI 14.220 € (+3,04 %)     VALLOUREC 24.200 € (+0,67 %)     MAAT PHARMA 3.160 € (-2,92 %)     ESSILORLUXOTTICA 175.500 € (+1,30 %)     RIBER 16.220 € (+5,60 %)     INPOST 15.370 € (+0,20 %)     TOTALENERGIES 77.230 € (-1,81 %)     CREDIT AGRICOLE 17.550 € (+1,68 %)     MOTA ENGIL 4.816 € (+3,35 %)     ELIOR GROUP 2.010 € (+1,52 %)     IMCD 91.340 € (+0,13 %)     INNATE PHARMA 1.604 € (-2,20 %)     LVMH 477.500 € (+1,04 %)     NN GROUP 74.400 € (-1,90 %)     ASR NEDERLAND 65.880 € (+0,18 %)     EMEIS 14.990 € (+1,97 %)  
News Réglementées
07/05/2026 13:50

Advaita Bio Launches iSCanGuide™: Unified Single-Cell and Spatial Transcriptomics Analysis, Powered by GPU-Accelerated Infrastructure

EQS-News: Advaita Bio / Key word(s): Product Launch
Advaita Bio Launches iSCanGuide™: Unified Single-Cell and Spatial Transcriptomics Analysis, Powered by GPU-Accelerated Infrastructure

07.05.2026 / 13:50 CET/CEST
The issuer is solely responsible for the content of this announcement.


GPU-Accelerated Platform Unifies Fragmented Workflows, Turning Weeks of Analysis into Minutes

ANN ARBOR, Mich., May 7, 2026 /PRNewswire/ -- Advaita Bio today announced the launch of iSCanGuide, a cloud-based platform engineered to transform large-scale single-cell and spatial transcriptomics datasets into biologically meaningful results. Built on 20 years of validated science, the platform is integrated with Advaita's flagship platform, iPathwayGuide, replacing fragmented workflows with a unified, GPU-powered discovery environment.

Advaita Logo

Single-cell and spatial transcriptomics generate complex datasets — but most researchers are still stitching together fragmented tools to analyze them, writing custom scripts, exporting between platforms, and losing weeks to manual workflows. iSCanGuide eliminates that bottleneck with a unified, GPU-accelerated environment that turns what used to take weeks into minutes, built on the same validated science that underpins Advaita's pathway analysis platform, trusted by over 13,000 researchers worldwide.

"Researchers are drowning in data and starving for insight," said Mike Mattacola, CEO of Advaita Bio. "iSCanGuide collapses what used to be a weeks-long manual process into minutes — from count matrices to annotated cell types, spatial context, and mechanistic pathway analysis in a single platform."

Key Features & Compatibility:

  • Real-Time Interaction: GUI-driven, zero-code interface with multiple navigation modes — accessible enough for first-time users, powerful for expert analysis.
  • Standardized Best-Practice Workflows: Ensure reproducibility and consistency across single-cell and spatial transcriptomics experiments with standardized, validated analysis pipelines.
  • Single-Cell Transcriptomics Analysis: Natively supports .h5ad, .h5, 10x CellRanger, and ParseBio outputs, enabling interactive and iterative analysis from initial QC and filtering through clustering, annotation, and trajectory analysis, with flexible workflows that adapt to your data at every stage.
  • Spatial Transcriptomics Analysis: Map gene expression in its native tissue context with full support for 10x Genomics Visium (Standard/HD) and Xenium. Visualize spatial cell distributions and identify spatially variable genes — all within the same environment used for single-cell RNA-seq, with no data export required.
  • Integrated Frameworks: Feeds directly into iPathwayGuide™ proprietary Impact Analysis methodology for mechanistic pathway analysis at single-cell resolution — connecting cell type annotation to pathway-level biological interpretation in a single workflow.
  • Cell-to-Cell Communication Analysis: Characterise intercellular signalling networks by identifying ligand-receptor interactions and communication patterns across cell types — revealing how cells coordinate behaviour within their native tissue environment.

"Single-cell and spatial analysis has been defined by fragmentation — too many tools, too many parameters, and no continuity between clustering and biological interpretation. The steep learning curve means critical know-how walks out the door every time an analyst leaves, and sharing results is harder than it should be," said Dr. Sorin Draghici, Founder and Chief Scientific Officer. "iSCanGuide replaces all of that with a single platform that takes researchers from count matrices to mechanistic pathway understanding — with sensible defaults, one-click sharing, and every setting captured. It connects directly to iPathwayGuide's proprietary Impact Analysis methodology, so the entire workflow runs in minutes rather than weeks."

To learn more about iSCanGuide, please visit our website.

About Advaita Bio

Advaita Bio builds AI-powered software for pathway analysis, variant interpretation, and single-cell analytics. Trusted by over 13,000 researchers and backed by nearly 20,000 peer-reviewed citations, the platform is built on two decades of scientifically validated algorithms to deliver biological insight that conventional tools miss.

Media contact

pr@advaitabio.com

Logo - https://mma.prnewswire.com/media/2974032/Advaita_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/advaita-bio-launches-iscanguide-unified-single-cell-and-spatial-transcriptomics-analysis-powered-by-gpu-accelerated-infrastructure-302764555.html

rt.gif?NewsItemId=EN52968&Transmission_Id=202605070745PR_NEWS_EURO_ND__EN52968&DateId=20260507


07.05.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2323312  07.05.2026 CET/CEST

Source : Webdisclosure.com

© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière